Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Panitumumab.

Yu Jo Chua1, David Cunningham

  • 1Department of Medicine, Royal Marsden Hospital, London and Surrey, UK. yujo.chua@rmh.nhs.uk

Drugs of Today (Barcelona, Spain : 1998)
|December 16, 2006
PubMed
Summary
This summary is machine-generated.

Panitumumab, a fully human monoclonal antibody targeting epidermal growth factor receptor (EGFR), significantly improved progression-free survival in metastatic colorectal cancer patients. Rash severity may predict treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma.

The British journal of surgery·2022
Same author

Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma.

Cancers·2022
Same author

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.

Nature cancer·2022
Same author

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.

Nature cancer·2022
Same author

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.

Lancet (London, England)·2022
Same author

Heat increases full-length SMN splicing: promise for splice-augmenting therapies for SMA.

Human genetics·2022
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular targeted therapy

Background:

  • Epidermal Growth Factor Receptor (EGFR) is implicated in solid tumor development and progression.
  • Panitumumab is a fully human monoclonal antibody targeting EGFR.
  • EGFR is overexpressed in several solid tumors, including colorectal cancer.

Purpose of the Study:

  • To review the rationale for targeting EGFR and the development of panitumumab.
  • To discuss clinical trial results of panitumumab in colorectal cancer.
  • To summarize treatment-associated rash and its predictive value.

Main Methods:

  • Phase III trial in metastatic colorectal cancer patients with prior oxaliplatin/irinotecan-based therapy failure.
  • Randomization to panitumumab plus best-supportive care versus best-supportive care alone.

Related Experiment Videos

  • Review of preclinical and early phase trial data for panitumumab.

    • Main Results:

    • Panitumumab demonstrated a significant improvement in progression-free survival.
    • Rash occurred in up to 100% of patients, similar to cetuximab.
    • EGFR immunohistochemistry staining was not predictive of patient selection.

    Conclusions:

    • Panitumumab is an effective treatment for metastatic colorectal cancer.
    • Rash severity may serve as a predictive biomarker for treatment response.
    • Further trials are investigating panitumumab in combination therapies for first-line treatment.